Daily Stock Analysis, BSTC, Biospecifics Technologies Corp, priceseries

Biospecifics Technologies Corp. Daily Stock Analysis
Stock Information
Open
54.47
Close
54.50
High
54.91
Low
54.00
Previous Close
53.87
Daily Price Gain
0.63
YTD High
58.21
YTD High Date
Jan 4, 2017
YTD Low
48.75
YTD Low Date
Feb 8, 2017
YTD Price Change
-1.87
YTD Gain
-3.32%
52 Week High
58.21
52 Week High Date
Jan 4, 2017
52 Week Low
32.39
52 Week Low Date
May 19, 2016
52 Week Price Change
18.58
52 Week Gain
51.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 22. 2015
38.93
Jun 26. 2015
51.08
24 Trading Days
31.22%
Link
LONG
Jul 16. 2015
51.87
Aug 5. 2015
63.99
14 Trading Days
23.36%
Link
LONG
May 20. 2016
35.07
Jun 9. 2016
37.84
13 Trading Days
7.90%
Link
LONG
Sep 12. 2016
37.28
Oct 11. 2016
45.72
21 Trading Days
22.65%
Link
Company Information
Stock Symbol
BSTC
Exchange
NasdaqGM
Company URL
www.biospecifics.com
Company Phone
5165937000
CEO
Thomas L. Wegman
Headquarters
New York
Business Address
35 WILBUR ST, LYNBROOK, NY 11563
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000875622
About

BioSpecifics Technologies Corp. is a biopharmaceutical company, which engages in development of an injectable collagenase for multiple indications. Its product XIAFLEX is an injectable collagenase enzyme, which is used for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm. The company was founded in 1990 and is headquartered in Lynbrook, NY.

Description

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.